Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Melanoma and Nonmelanoma Skin Cancer: A Propensity Score–Matched Cohort Study
- 27 September 2026
- journal article
- Published by Wiley in Diabetes, Obesity and Metabolism
Abstract
No abstract availableKeywords
This publication has 3 references indexed in Scilit:
- Incretin signaling at the crossroads of metabolism, inflammation, and tumorigenesis: implications for obesity patientsEuropean Journal of Pharmacology, 2025
- Prevention of cardiorenal complications in people with type 2 diabetes and obesityCell Metabolism, 2024
- Glucagon like peptide‐1 receptor agonists and the risk of skin cancer among patients with type 2 diabetes: Population‐based cohort studyDiabetic Medicine, 2023